Last updated: September 8, 2026
Desogestrel/ethinyl estradiol is a mature combined oral contraceptive marketed primarily through generic products in the United States and Europe. The molecule combination has no meaningful remaining innovator exclusivity, limited patent protection, and intense competition from levonorgestrel-, norgestimate-, drospirenone-, and norethindrone-based contraceptives. Revenue is concentrated in low-cost generic volume rather than premium pricing. The commercial outlook is stable in demand but weak in margin expansion.
What is the current market position of desogestrel and ethinyl estradiol?
Desogestrel/ethinyl estradiol is a prescription combined hormonal contraceptive containing an estrogen and a third-generation progestin. In the United States, it is sold under multiple generic and legacy brand names, including:
| Product or brand |
Typical dosage |
Market status |
| Apri |
Desogestrel 0.15 mg / ethinyl estradiol 0.03 mg |
Generic and legacy branded market |
| Isibloom |
Desogestrel 0.15 mg / ethinyl estradiol 0.03 mg |
Generic-label product |
| Emoquette |
Desogestrel 0.15 mg / ethinyl estradiol 0.03 mg |
Generic-label product |
| Reclipsen |
Desogestrel 0.15 mg / ethinyl estradiol 0.03 mg |
Generic-label product |
| Enskyce |
Desogestrel 0.15 mg / ethinyl estradiol 0.03 mg |
Generic-label product |
| Kariva, Azurette, Mircette-related products |
Variable 28-day regimens, including low-dose estrogen tablets |
Legacy branded or generic equivalents |
The product is available in 21-day and 28-day regimens. Some formulations use 21 active tablets followed by placebo tablets. Others include low-dose ethinyl estradiol tablets during the hormone-free interval.
In the United States, desogestrel/ethinyl estradiol competes in a large, mature oral contraceptive market. Competition is based on formulary position, pharmacy availability, copay, supply reliability, prescriber familiarity, and patient tolerability. Clinical differentiation is limited because the products have broadly similar contraceptive efficacy when taken correctly.
How large is the desogestrel and ethinyl estradiol market?
No major manufacturer reports desogestrel/ethinyl estradiol revenue as a separate product line. Public company filings generally aggregate oral contraceptive revenue with broader women’s health, generic, or prescription-product portfolios. Standalone global revenue therefore cannot be established from public financial filings.
The commercial market has four characteristics:
- Demand is recurring because contraceptive users typically refill monthly or quarterly.
- Unit volume is relatively resilient to economic cycles.
- Average selling prices are constrained by generic substitution and payer controls.
- Manufacturer profitability is sensitive to manufacturing reliability and customer concentration.
The United States market includes retail pharmacy, mail-order, Medicaid, commercial insurance, and cash-pay channels. Europe has broader country-level brand fragmentation and substantial pharmacy reimbursement control. In lower-income markets, oral contraceptives are often supplied through public-sector procurement, international health programs, and low-price generic channels.
The financial trajectory is therefore best characterized as mature and volume-driven:
| Period |
Commercial condition |
Revenue implication |
| Innovator launch and early lifecycle |
Brand pricing, marketing, physician promotion |
Higher gross margin |
| Generic entry |
Multiple ANDA or national generic competitors |
Rapid price erosion |
| Mature generic phase |
Stable refill demand and retailer contracting |
Low-to-moderate revenue stability |
| Supply disruption phase |
Manufacturer exits or API constraints |
Temporary price and share volatility |
| Long-term market |
Continued contraceptive demand and broad substitution |
Low growth, limited pricing power |
When did desogestrel and ethinyl estradiol lose exclusivity?
The combination lost practical innovator exclusivity years ago. Original products such as Mircette and related formulations were approved in the late 1990s and early 2000s. The relevant market is now dominated by generic-equivalent products.
There is no current commercial value attributable to a remaining new chemical entity exclusivity period. The combination is also too old to retain meaningful market protection from the original formulation approvals.
What is the Orange Book status of desogestrel and ethinyl estradiol?
FDA Orange Book treatment is product-specific because each strength, dosage regimen, and sponsor may have a separate NDA or ANDA record. The practical status is:
- Multiple generic products have been approved through the ANDA pathway.
- Original brand-related patents and regulatory exclusivity periods have expired.
- No current Orange Book-listed patent appears to create a broad market block against generic desogestrel/ethinyl estradiol.
- Any surviving formulation or method-of-use listing would be narrow and unlikely to restore brand-level exclusivity.
FDA approval records and labeling for combination oral contraceptives identify contraindications, thromboembolic risk, dosing regimens, and drug-interaction warnings. The product remains prescription-only in the United States. FDA approval of the over-the-counter progestin-only pill Opill in 2023 does not convert desogestrel/ethinyl estradiol products to over-the-counter status.[1][2]
What patents protect desogestrel and ethinyl estradiol products?
The core active ingredients are not protected by commercially meaningful U.S. composition-of-matter patents. Potential patent protection in this field historically centered on:
- Extended or modified dosing schedules
- Low-dose estrogen regimens
- Packaging and tablet sequencing
- Alternative hormone-free intervals
- Methods of reducing withdrawal bleeding
- Specific formulations or delivery systems
- Manufacturing processes and solid-state characteristics
Those categories can support narrow patents, but they do not recreate exclusivity over the basic combination of desogestrel and ethinyl estradiol.
What formulation patents are relevant?
Formulation differentiation has generally involved the dosing schedule rather than a technically complex delivery system. Mircette-type regimens use active hormone tablets followed by low-dose ethinyl estradiol and placebo tablets. That design can produce a distinct product presentation and dosing regimen, but generic approval pathways allow substantial competition where the regulatory product requirements are met.
The product does not depend on a biologic manufacturing process, device platform, depot system, or complex drug-device combination. Manufacturing barriers are therefore modest compared with those for injectable contraceptives, transdermal systems, implants, or biologics.
Are there Paragraph IV challenges for desogestrel and ethinyl estradiol?
Paragraph IV litigation is not a major current market driver for the basic combination. Generic entry occurred after the relevant innovator protections had expired or become commercially immaterial. The combination is now in the mature generic phase rather than the contested pre-entry phase.
A new Paragraph IV dispute could arise around a branded reformulation, a novel dosing regimen, or a proprietary packaging system. Such a dispute would concern the specific product claims, not the underlying desogestrel/ethinyl estradiol combination.
The absence of major current Paragraph IV activity means that competitive pressure comes primarily from:
- Additional ANDA approvals
- Generic price bidding
- Pharmacy benefit manager contracting
- Manufacturer supply capacity
- State Medicaid and public-sector procurement
- Product recalls or shortages
Which companies compete in the desogestrel and ethinyl estradiol market?
Competition is fragmented. Products have been marketed or supplied by companies including Teva, Lupin, Amneal, Glenmark, Prasco, Xiromed, and other generic manufacturers, depending on the country, product label, and distribution period.
The competitive set is broader than the molecule combination itself.
| Competitor class |
Representative products |
Competitive effect |
| Levonorgestrel/ethinyl estradiol |
Levora, Portia, Altavera and generics |
Strong low-cost substitute |
| Norgestimate/ethinyl estradiol |
Ortho-Cyclen, Sprintec and generics |
Large generic presence |
| Drospirenone/ethinyl estradiol |
Yaz, Yasmin and generics |
Differentiated by acne and premenstrual symptom positioning |
| Norethindrone/ethinyl estradiol |
Loestrin-related products and generics |
Broad formulary presence |
| Progestin-only pills |
Opill and generic norethindrone products |
Expands non-estrogen competition |
| Long-acting reversible contraceptives |
IUDs and implants |
Reduces reliance on daily oral dosing |
Clinical guidelines recognize that contraceptive selection must account for medical history, thrombotic risk, migraine status, smoking, age, postpartum status, and medication interactions.[3][4] This creates therapeutic segmentation even when products are pharmacologically substitutable.
How does desogestrel and ethinyl estradiol compare with levonorgestrel and ethinyl estradiol?
The primary commercial distinction is safety perception and prescriber preference rather than efficacy.
| Attribute |
Desogestrel/ethinyl estradiol |
Levonorgestrel/ethinyl estradiol |
| Progestin generation |
Third generation |
Second generation |
| Generic availability |
Extensive |
Extensive |
| Price pressure |
High |
High |
| Contraceptive efficacy |
Comparable with correct use |
Comparable with correct use |
| Venous thromboembolism profile |
Generally viewed as less favorable than levonorgestrel combinations |
Often preferred when minimizing relative VTE risk |
| Prescriber use |
Established but selective |
Broad first-line generic use |
| Commercial positioning |
Mature, low-price product |
Mature, highly competitive product |
Several analyses have reported a higher relative venous thromboembolism risk for desogestrel-containing combined oral contraceptives than for levonorgestrel-containing products, although absolute risk remains dependent on patient characteristics and pregnancy-related risk is also relevant.[5] This safety differentiation can limit premium positioning for desogestrel products.
What is the FDA regulatory status of the product?
Desogestrel/ethinyl estradiol products are FDA-approved prescription combined oral contraceptives. FDA labeling contains contraindications for patients with specific thrombotic, cardiovascular, hepatic, migraine-related, and smoking-related risks.
Key regulatory characteristics include:
- ANDA-based generic competition
- Demonstration of pharmaceutical equivalence and bioequivalence
- Prescription-only status
- Periodic labeling updates driven by safety information
- No biosimilar pathway
- No requirement for biologic comparability studies
FDA approval of Opill, a norgestrel progestin-only pill, created an over-the-counter contraceptive alternative but not a direct OTC version of desogestrel/ethinyl estradiol.[1]
What litigation or settlement agreements affect the product?
There is no widely reported active litigation campaign that materially constrains the basic desogestrel/ethinyl estradiol market. Historical disputes involving oral contraceptives have generally concerned:
- Product liability and thromboembolism claims
- Failure-to-warn allegations
- Brand-to-generic substitution
- Formulation-specific patent disputes
- Manufacturing quality and recall matters
Product liability exposure remains commercially relevant because combined hormonal contraceptives carry known thromboembolic and cardiovascular warnings. That exposure affects insurance, reserves, labeling strategy, and corporate risk but does not ordinarily produce market exclusivity.
No settlement agreement is known to delay broad generic entry for the mature combination.
How strong is the patent estate for desogestrel and ethinyl estradiol?
The patent estate is weak for the base combination and potentially stronger only for narrow product variations.
| Patent category |
Current commercial strength |
| Core active ingredients |
Minimal |
| Basic tablet combination |
Minimal |
| Standard 21/7 regimen |
Minimal |
| Low-dose estrogen or staged regimen |
Potentially narrow |
| Packaging and tablet sequencing |
Narrow and design-dependent |
| Manufacturing process |
Usually nonblocking |
| Method-of-use claims |
Limited by clinical and labeling scope |
| Biologic or biosimilar protection |
Not applicable |
The principal barriers are regulatory execution, supply consistency, customer access, and quality compliance rather than patent exclusion.
What is the financial trajectory for manufacturers?
For manufacturers, desogestrel/ethinyl estradiol is generally a defensive or portfolio product rather than a major growth asset. Financial performance depends on volume retention and cost control.
The expected trajectory is:
- Flat to modestly declining nominal revenue in a mature market
- Continued unit demand from established contraceptive users
- Low gross margins where several suppliers compete
- Occasional price increases during shortages
- Limited ability to sustain price increases after supply normalizes
- Higher value for distributors with broad contraceptive portfolios than for a single-product manufacturer
Revenue exposure is material only for companies that aggregate many oral contraceptive products or hold substantial pharmacy-channel contracts. For diversified pharmaceutical companies, the product is unlikely to be individually material unless a supply disruption temporarily increases market share or pricing.
The greatest financial risks are manufacturing interruptions, API sourcing problems, regulatory observations, recalls, and loss of a large wholesaler or payer contract. The greatest upside is temporary share capture following competitor exit or shortage.
What generic launch scenarios exist?
Base case
Multiple generic suppliers remain active. Prices stay low, prescriptions remain stable, and manufacturers compete through supply reliability and contracting. Revenue is broadly flat or gradually declining.
Upside case
One or more competitors leave the market, experience a recall, or face capacity constraints. Remaining suppliers gain volume and may obtain temporary price increases. The effect is usually short-lived because additional generic capacity can re-enter.
Downside case
Payers favor alternative contraceptive combinations, prescribers shift toward long-acting methods or progestin-only products, and manufacturers reduce participation because of low margins. Volume declines while price competition remains intense.
Reformulation case
A company introduces a differentiated regimen, new packaging, or a product with a distinct regulatory or patient-use profile. Commercial success would depend on clinical convenience and reimbursement rather than the old combination's patent estate.
What biosimilar risks exist?
No biosimilar risk applies. Desogestrel/ethinyl estradiol is a small-molecule drug, not a biologic. The relevant competitive threats are generic ANDA products, therapeutic substitutes, OTC contraceptives, long-acting contraceptive methods, and branded reformulations.
What geographic markets are most relevant?
The United States is important because of high generic substitution, centralized pharmacy distribution, and extensive FDA-approved product competition. Europe has a fragmented regulatory and reimbursement environment, with country-specific brands and national procurement systems. Latin America and parts of Asia have significant oral contraceptive use but greater variation in public-sector distribution, branded generics, and out-of-pocket purchasing.
The combination's geographic commercial strength is not determined by patent protection. It depends on registration status, local manufacturing, tender participation, pharmacovigilance capability, and distributor relationships.
Key Takeaways
- Desogestrel/ethinyl estradiol is a mature, genericized combined oral contraceptive.
- Core patent and regulatory exclusivity have expired.
- Current commercial value is driven by recurring volume, not premium pricing.
- The product has no biosimilar exposure and limited active patent risk.
- Levonorgestrel/ethinyl estradiol is a major lower-cost competitor and is often favored when relative VTE risk is a concern.
- FDA status remains prescription-only for desogestrel/ethinyl estradiol.
- Opill creates OTC category competition but is not the same active combination.
- Standalone revenue is generally not disclosed by manufacturers.
- Profitability depends on supply reliability, manufacturing cost, contracting, and competitor exits.
- The base-case financial outlook is stable demand with low growth and persistent margin pressure.
FAQs
Is desogestrel and ethinyl estradiol still patented?
The active ingredients and basic combination are no longer protected by commercially meaningful core patents. Narrow patents could apply to specific regimens, packaging, or formulations.
Is desogestrel and ethinyl estradiol available over the counter?
In the United States, it remains prescription-only. FDA approval of Opill applies to a progestin-only product containing norgestrel, not to desogestrel/ethinyl estradiol.
Is desogestrel and ethinyl estradiol more expensive than levonorgestrel and ethinyl estradiol?
Both combinations are broadly available as low-cost generics. Actual patient cost depends on the manufacturer, insurance plan, pharmacy benefit manager, deductible, and local market.
Does desogestrel and ethinyl estradiol have higher blood-clot risk?
Evidence generally places desogestrel-containing combined oral contraceptives at a higher relative VTE risk than levonorgestrel-containing products. Individual risk depends on age, smoking, migraine, obesity, prior thrombosis, postpartum status, and other clinical factors.[3][5]
Can a generic manufacturer obtain meaningful pricing power?
Only temporarily in most cases. Pricing power can emerge during shortages, recalls, or competitor exits, but mature generic competition usually restores price pressure once supply normalizes.
References
- U.S. Food and Drug Administration. (2023). FDA approves first nonprescription daily oral contraceptive. https://www.fda.gov
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA and Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov
- Centers for Disease Control and Prevention. (2024). U.S. medical eligibility criteria for contraceptive use, 2024. MMWR Recommendations and Reports, 73(4). https://www.cdc.gov/mmwr
- World Health Organization. (2015). Medical eligibility criteria for contraceptive use (5th ed.). World Health Organization.
- Stegeman, B. H., de Bastos, M., Rosendaal, F. R., van Hylckama Vlieg, A., Helmerhorst, F. M., Stijnen, T., & Dekkers, O. M. (2013). Different combined oral contraceptives and the risk of venous thrombosis: Systematic review and network meta-analysis. BMJ, 347, f5298. https://doi.org/10.1136/bmj.f5298
